-
公开(公告)号:US11860169B2
公开(公告)日:2024-01-02
申请号:US17015006
申请日:2020-09-08
申请人: Chu Sainte-Justine
IPC分类号: G01N33/68 , G01N33/487 , G01N33/53 , A61F5/02 , A61K31/4045 , A61K33/04 , A61K45/06 , A61K31/713 , A61K38/19 , C12N15/113 , A61K38/08
CPC分类号: G01N33/6893 , A61F5/02 , A61F5/026 , A61K31/4045 , A61K31/713 , A61K33/04 , A61K38/19 , A61K45/06 , C12N15/1138 , G01N33/48728 , A61K38/08 , C12N2310/14 , C12N2320/30 , G01N33/53 , G01N2333/04 , G01N2333/726 , G01N2800/10 , G01N2800/50 , G01N2800/52 , A61K31/4045 , A61K2300/00 , A61K31/713 , A61K2300/00 , A61K33/04 , A61K2300/00
摘要: The present invention provides a method of treating a subject in need thereof comprising classifying the subject into functional group FG1, FG2 or FG3, wherein i) when the subject is classified into the FG1 functional group, (A) the level of OPN or the activity of OPN in said subject is increased; (B) the subject is not treated with a brace; or (C) a combination of (A) and (B); and ii) when the subject is classified into the FG2 or FG3 functional group, (A) the level of OPN or the activity of OPN in said subject is decreased; (B) the subject is treated with a brace; or (C) a combination of (A) and (B).
-
公开(公告)号:US09261510B2
公开(公告)日:2016-02-16
申请号:US12104751
申请日:2008-04-17
CPC分类号: G01N33/6854 , C07K14/20 , C07K14/245 , C07K14/45 , C07K14/47 , C07K2319/70 , C12N15/62 , C12N2710/16122 , C12N2710/16134 , G01N2333/02 , G01N2333/035 , G01N2333/04 , G01N2333/045 , G01N2333/05 , G01N2333/19 , G01N2333/45
摘要: The present invention relates to fusion proteins suitable as test antigens in the detection of infections with pathogens, particularly of primary infections with pathogens. Further, the invention relates to methods for detecting and differentially determining antibodies, particularly IgM antibodies resulting from an infection with a pathogenic organism. Furthermore, test reagents for carrying out these methods are provided.
摘要翻译: 本发明涉及适合作为检测抗原的融合蛋白,用于检测病原体的感染,特别是病原体的初次感染。 此外,本发明涉及用于检测和差异测定抗体的方法,特别是由致病性生物体的感染产生的IgM抗体。 此外,提供了用于实施这些方法的测试试剂。
-
公开(公告)号:US20120171302A1
公开(公告)日:2012-07-05
申请号:US13332858
申请日:2011-12-21
申请人: Jongyun Heo
发明人: Jongyun Heo
IPC分类号: A61K31/522 , A61K33/00 , A61K33/40 , G01N33/53 , A61P35/04 , A61P9/12 , A61P37/00 , C12Q1/34 , A61K31/52 , A61P35/00
CPC分类号: A61K31/52 , A61K31/15 , A61K31/522 , A61K33/00 , A61K33/40 , A61K45/06 , C12Q1/34 , G01N2333/04 , A61K2300/00
摘要: The invention provides compositions for inhibiting a redox-sensitive GTPase protein, including a Rho or Rab family GTPase, comprising an effective amount of a redox-sensitive purine compound and an effective amount of a redox agent. The invention further provides methods of inhibiting a redox-sensitive GTPase protein, including a Rho or Rab family GTPase, by administering compositions of the invention. Methods of screening for compounds that inhibit a redox-sensitive GTPase protein, including compounds that target and inhibit Rho or Rab family GTPases, are further provided.
摘要翻译: 本发明提供用于抑制包含Rho或Rab家族GTP酶的氧化还原敏感性GTP酶蛋白质的组合物,其包含有效量的氧化还原敏感性嘌呤化合物和有效量的氧化还原剂。 本发明还通过施用本发明的组合物提供了抑制包含Rho或Rab家族GTP酶的氧化还原敏感性GTP酶蛋白质的方法。 还提供了筛选抑制氧化还原敏感性GTP酶蛋白质的化合物的方法,包括靶向和抑制Rho或Rab家族GTP酶的化合物。
-
4.
公开(公告)号:US20240294602A1
公开(公告)日:2024-09-05
申请号:US18647837
申请日:2024-04-26
发明人: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC分类号: C07K14/74 , A01N37/46 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/17 , A61K39/00 , A61K45/06 , C07K7/02 , C07K7/06 , C07K14/00 , C07K14/47 , C07K14/725 , C07K16/18 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N9/64 , C12Q1/6886 , G01N33/50 , G01N33/566 , G01N33/569
CPC分类号: C07K14/70539 , A01N37/46 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12Q1/6886 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , A61K38/00 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2501/998 , C12N2502/11 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N2333/04 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
摘要: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
公开(公告)号:US11897934B2
公开(公告)日:2024-02-13
申请号:US17172621
申请日:2021-02-10
发明人: Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号: C07K14/70 , C07K14/74 , G01N33/569 , A61K39/00 , C07K16/28 , A61K45/06 , A01N37/46 , C07K14/725 , C12Q1/6886 , C07K14/47 , C07K16/30 , A61K38/08 , C07K7/02 , C07K7/06 , G01N33/566 , C07K16/18 , C12N5/0783 , C12N9/64 , C07K14/00 , A61K38/17 , G01N33/50 , A61K38/06 , A61K38/00
CPC分类号: C07K14/70539 , A01N37/46 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12Q1/6886 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , A61K38/00 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2501/998 , C12N2502/11 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N2333/04 , G01N2333/7051 , G01N2333/70503 , G01N2333/70539 , G01N2500/10
摘要: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
公开(公告)号:US20140200230A1
公开(公告)日:2014-07-17
申请号:US14227712
申请日:2014-03-27
申请人: Jongyun Heo
发明人: Jongyun Heo
CPC分类号: A61K31/52 , A61K31/15 , A61K31/522 , A61K33/00 , A61K33/40 , A61K45/06 , C12Q1/34 , G01N2333/04 , A61K2300/00
摘要: The invention provides compositions for inhibiting a redox-sensitive GTPase protein, including a Rho or Rab family GTPase, comprising an effective amount of a redox-sensitive purine compound and an effective amount of a redox agent. The invention further provides methods of inhibiting a redox-sensitive GTPase protein, including a Rho or Rab family GTPase, by administering compositions of the invention. Methods of screening for compounds that inhibit a redox-sensitive GTPase protein, including compounds that target and inhibit Rho or Rab family GTPases, are further provided.
摘要翻译: 本发明提供用于抑制包含Rho或Rab家族GTP酶的氧化还原敏感性GTP酶蛋白质的组合物,其包含有效量的氧化还原敏感性嘌呤化合物和有效量的氧化还原剂。 本发明还通过施用本发明的组合物提供了抑制包含Rho或Rab家族GTP酶的氧化还原敏感性GTP酶蛋白质的方法。 还提供了筛选抑制氧化还原敏感性GTP酶蛋白质的化合物的方法,包括靶向和抑制Rho或Rab家族GTP酶的化合物。
-
公开(公告)号:US20060100422A1
公开(公告)日:2006-05-11
申请号:US11180275
申请日:2005-07-13
申请人: Steven Goldberg , Paul Cino , Ramesh Patel , Venkata Nanduri , Robert Johnston
发明人: Steven Goldberg , Paul Cino , Ramesh Patel , Venkata Nanduri , Robert Johnston
CPC分类号: C12N9/0004 , C12Q1/26 , G01N2333/04
摘要: This invention relates to a recombinant Pichia pastoris formate dehydrogenase (FDH) enzyme that catalyzes the oxidation of formate to carbon dioxide and the simultaneous reduction of nicotinamide adenine dinucleotide (NAD+) to its reduced form (NADH). Also related are isolated nucleic acids encoding P. pastoris FDH polypeptides, and fragments and variants thereof, as well as vectors and host cells comprising these nucleic acids. Further related are isolated, recombinant P. pastoris FDH polypeptides, and fragments and variants thereof, and antibodies that specifically bind to P. pastoris FDH polypeptides, fragments, or variants. The invention also relates to methods of obtaining isolated P. pastoris FDH nucleic acids, polypeptides, and antibodies, and methods of using P. pastoris FDH in various reactions for industrial or pharmaceutical applications.
-
8.
公开(公告)号:US06713250B1
公开(公告)日:2004-03-30
申请号:US08907783
申请日:1997-08-08
申请人: Richard S. Kalish
发明人: Richard S. Kalish
IPC分类号: C12Q168
CPC分类号: G01N33/56977 , G01N33/5047 , G01N2333/035 , G01N2333/04 , G01N2333/045 , G01N2333/16 , G01N2333/31 , G01N2333/35
摘要: The invention provides a method for screening a test compound for the ability of the test compound to induce a response from human naive T-cells. The method comprises admixing human naive T cells, macrophages/monocytes, immortalized B cells lacking class I and class II major histocompatibility antigens, and a test compound; and determining whether the test compound induces a response from the human naive T cells. The invention further provides a method for primary in vitro sensitization of human naive T-cells. The method comprises admixing human naive T cells, macrophages/monocytes, immortalized B cells lacking class I and class II major histocompatibility antigens, and an antigen.
摘要翻译: 本发明提供了一种用于筛选测试化合物以测试化合物诱导人类天真T细胞应答的能力的方法。 该方法包括混合人原始T细胞,巨噬细胞/单核细胞,缺乏I类和II类主要组织相容性抗原的永生化B细胞和测试化合物; 以及确定测试化合物是否诱导来自人天真T细胞的反应。 本发明还提供了一种用于初始体外致敏的人类天真T细胞的方法。 该方法包括混合人原始T细胞,巨噬细胞/单核细胞,缺乏I类和II类主要组织相容性抗原的永生化B细胞和抗原。
-
公开(公告)号:US20040038237A1
公开(公告)日:2004-02-26
申请号:US10320300
申请日:2002-12-16
IPC分类号: C12Q001/68 , C07H021/04 , C12N009/02 , C12P021/02 , C12N005/06
CPC分类号: C12N9/0004 , C12Q1/26 , G01N2333/04
摘要: This invention relates to a recombinant Pichia pastoris formate dehydrogenase (FDH) enzyme that catalyzes the oxidation of formate to carbon dioxide and the simultaneous reduction of nicotinamide adenine dinucleotide (NADnull) to its reduced form (NADH). Also related are isolated nucleic acids encoding P. pastoris FDH polypeptides, and fragments and variants thereof, as well as vectors and host cells comprising these nucleic acids. Further related are isolated, recombinant P. pastoris FDH polypeptides, and fragments and variants thereof, and antibodies that specifically bind to P. pastoris FDH polypeptides, fragments, or variants. The invention also relates to methods of obtaining isolated P. pastoris FDH nucleic acids, polypeptides, and antibodies, and methods of using P. pastoris FDH in various reactions for industrial or pharmaceutical applications.
摘要翻译: 本发明涉及催化甲酸氧化成二氧化碳并同时将烟酰胺腺嘌呤二核苷酸(NAD +)还原为还原形式(NADH)的重组巴斯德毕赤酵母甲酸脱氢酶(FDH)酶。 还涉及编码巴斯德毕赤酵母多肽的分离的核酸及其片段和变体,以及包含这些核酸的载体和宿主细胞。 进一步相关的是分离的重组巴斯德毕赤酵母FDH多肽及其片段和变体,以及特异性结合巴斯德毕赤酵母多肽,片段或变体的抗体。 本发明还涉及获得分离的巴斯德毕赤酵母FDH核酸,多肽和抗体的方法,以及在工业或药物应用的各种反应中使用巴斯德毕赤酵母FDH的方法。
-
公开(公告)号:US11873329B2
公开(公告)日:2024-01-16
申请号:US17172577
申请日:2021-02-10
发明人: Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号: C07K14/705 , C07K14/74 , G01N33/569 , A61K39/00 , C07K16/28 , A61K45/06 , A01N37/46 , C07K14/725 , C12Q1/6886 , C07K14/47 , C07K16/30 , A61K38/08 , C07K7/02 , C07K7/06 , G01N33/566 , C07K16/18 , C12N5/0783 , C12N9/64 , C07K14/00 , A61K38/17 , G01N33/50 , A61K38/06 , A61K38/00
CPC分类号: C07K14/70539 , A01N37/46 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12Q1/6886 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , A61K38/00 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2501/998 , C12N2502/11 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N2333/04 , G01N2333/7051 , G01N2333/70503 , G01N2333/70539 , G01N2500/10
摘要: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
-
-
-
-
-
-
-
-